Abstracts by key term: innovation
Wer sich auf die Suche nach dem wissenschaftlichen Verständnis des Begriffs Innovation begibt, stößt schnell auf Joseph Schumpeters „Theorie der Innovationen“, die Innovation als willentlichen und gezielten Veränderungsprozess hin zu etwas Erstmaligem, Neuem versteht. Wobei Wirtschaft und Gesellschaft sich in diesem Verständnis dadurch wandeln, dass Produktionsfaktoren auf eine neuartige Art und Weise kombiniert werden. Dabei ist es von zentraler Bedeutung, dass erst dann von Innovation (in Abgrenzung zur Invention) gesprochen werden kann, wenn der Nutzen einer Neuentwicklung erkannt wurde und die Veränderung im Markt angekommen ist. [1] Diese Erschließung von neuen Ideen und Perspektiven über die Grenzen unterschiedlicher Bereiche hinweg hat sich auch der Innovationsfonds des G-BA zu eigen gemacht – mit dem Ziel, den Wettbewerb um die besten Ideen anzutreiben und kontinuierliche Innovation in das Gesundheitssystem einzubringen: „Auf diese Weise wirkt der Innovationsfonds als kraftvoller Motor für eine bessere Patientenversorgung in Deutschland.“ [2]
01.02.2026
The German healthcare system performs well in international comparisons in terms of quality and efficiency, but comparative studies point to existing potential for optimization (Lauerer et al. 2013: 483–491; Manouguian et al. 2010). Trends such as demographic change, which poses new challenges for regional supply security, require a continuous improvement in the supply structure and quality (Stüve 2009: 51–60; Amelung/Wolf 2011: 1566–1572). In order to do justice to this, politicians are calling for stronger networking and cooperation between service providers in the form of integrated care models (Amelung et al. 2009; Mühlbacher 2002). Various studies view interconnected structural, product and process innovations as necessary in order to significantly increase efficiency and effectiveness (Omachonu/Objection 2010: 1-20; Varkey et al. 2008: 382-388; Ilinca et al. 2012: 193 –202). Innovations, which are defined as the successful implementation of a new idea in a way that increases value for some or all participants, are no longer initiated only by individual actors, but are increasingly developed and disseminated in cooperative networks (Akrich et al. 2002: 187-206 ; Varkey et al. 2008: 382–388). With the aim of improving medical care, EU, federal and state policies promote health innovations at all levels, but 40% of these only exist until the start-up funding runs out (Savaya et al. 2008: 478–493). This volatility of improvement initiatives negatively impacts society's support and trust in future projects (Shediac-Rizkallah/Bone 1998: 87-108). The high use of resources during the new introduction creates a legitimate demand for goal achievement and long-term success and increases the interest of stakeholders in the sustainability factor (Edwards et al. 2007: 37–47).
31.03.2016
The 2013 coalition agreement does not mention the words innovation and progress once in the “Health and Care” section (apart from the new innovation fund), but this aspect is given very broad consideration in the economic policy part of the agreement. The key point is the goal of investing at least 3 % of the gross domestic product in research and development in the future. In order to achieve this, the health care system is also mentioned very prominently in the contract, for which the federal government, for example, plans to promote innovative products and processes in the area of individualized medicine as well as gender and geriatric medicine. However, the question arises as to what effects such research initiatives have on actual care in the health system, i.e. whether the translation into the care context is successful and whether appropriate procedures and assessment methods are available to decide which innovations actually represent medical or social progress should therefore find their way into general care practice at all. This is the subject of health services research, which from a health economics perspective always involves weighing up the identified benefits of a measure and the resources required to implement it. The use of these findings varies greatly depending on the service sector in the healthcare system, which indicates that there is a need to catch up, which will be discussed in this article. The starting point should first be a brief distinction between innovation and progress, in order to then discuss what contribution cost and benefit analyzes can make in this distinction.
24.01.2013
On January 1, 2011, the law to reorganize the pharmaceutical market (AMNOG) came into force. Since the AMNOG came into force, pharmaceutical companies (companies) have had to submit evidence of the additional benefit of the new active ingredient for all drugs with new active ingredients as of the date of market launch. According to the draft bill for AMNOG, one of the objectives of this law was to create “reliable framework conditions for innovation, care for insured persons and job security” (1). The research-based pharmaceutical drug manufacturers have faced the extremely high administrative effort associated with dossier creation. In public statements, IQWiG certifies that the pharmaceutical companies' dossiers are of good quality. After three years of experience with early benefit assessment, the question now arises as to whether AMNOG is an obstacle or an accelerator for innovation.